Ocular photodynamic therapy - Standard applications and new indications (part 2): Review of the literature and personal experience

Ophthalmologica

Volumn 221, Issue 5, 2007, Pages 282-291

  Mennel, Stefan ^a   Barbazetto, Irene ^c   Meyer, Carsten H ^b   Peter, Silvia ^d   Stur, Michael ^e  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b UNIVERSITY OF BONN   (Germany)

^c Department of Orthopaedic Surgery   (United States)

^d Academic Hospital   (Austria)

^e MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Hemangioma, choroidal, capillary; Macular degeneration; Ocular photodynamic therapy, children; Retinal astrocytic hamartoma; Squamous cell carcinoma; Tuberous sclerosis; Uveal melanoma; Vasoproliferative tumor; Von Hippel Lindau disease

Indexed keywords

AMINOLEVULINIC ACID; ANECORTAVE; ANGIOGENESIS INHIBITOR; BENZOPORPHYRIN DERIVATIVE; BEVACIZUMAB; INDOCYANINE GREEN; PEGAPTANIB; RANIBIZUMAB; TRIAMCINOLONE; VASCULOTROPIN INHIBITOR;

BLINDNESS; CAPILLARY HEMANGIOMA; CENTRAL SEROUS RETINOPATHY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; EYE DISEASE; HEMANGIOMATOSIS; HUMAN; IRIS RUBEOSIS; MONOTHERAPY; MYOPIA; NEOVASCULAR GLAUCOMA; NERVE COMPRESSION; NONHUMAN; OPTIC NERVE COMPRESSION; PARAFOVEAL TELANGIECTASIA; PHOTODYNAMIC THERAPY; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; RETINA MACULA AGE RELATED DEGENERATION; RETINAL ASTROCYTIC HAMARTOMA; REVIEW; SQUAMOUS CELL CARCINOMA; SURGICAL TECHNIQUE; TREATMENT INDICATION; UVEA MELANOMA; VON HIPPEL LINDAU DISEASE;

EXUDATES AND TRANSUDATES; EYE DISEASES; EYE NEOPLASMS; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; PHOTOCHEMOTHERAPY;

EID: 34548299810     PISSN: 00303755     EISSN: None     Source Type: Journal    
DOI: 10.1159/000104757     Document Type: Review

References (76)

1. Mennel S, Hausmann N, Meyer CH, Peter S: Photodynamic therapy for exudative hamartoma in tuberous sclerosis. Arch Ophthalmol 2006;124:597-599.
2. Barbazetto I, Schmidt-Erfurth U: Photodynamic therapy of choroidal hemangioma: two case reports. Graefes Arch Clin Exp Ophthalmol 2000;238:214-221.
3. Madreperla SA: Choroidal hemangioma treated with photodynamic therapy using verteporfin. Arch Ophthalmol 2001;119:1606-1610.
4. Michels S, Michels R, Beckendorf A, Schmidt-Erfurth U: Photodynamic therapy for choroidal hemangioma: long-term results. Ophthalmologe 2004;101:569-575.
5. Michels S, Michels R, Simader C, Schmidt-Erfurth U: Verteporfin therapy for choroidal hemangioma: a long-term follow-up. Retina 2005;25:697-703.
6. Schmidt-Erfurth UM, Michels S, Kusserow C, Jurklies B, Augustin AJ: Photodynamic therapy for symptomatic choroidal hemangioma: visual and anatomic results. Ophthalmology 2002;109:2284-2294.
7. Gupta M, Singh AD, Rundle PA, Rennie IG: Efficacy of photodynamic therapy in circumscribed choroidal haemangioma. Eye 2004;18:139-142.
8. Jurklies B, Anastassiou G, Ortmans S, Schuler A, Schilling H, Schmidt-Erfurth U, Bornfeld N: Photodynamic therapy using verteporfin in circumscribed choroidal haemangioma. Br J Ophthalmol 2003;87:84-89.
9. Robertson DM: Photodynamic therapy for choroidal hemangioma associated with serous retinal detachment. Arch Ophthalmol 2002;120:1155-1161.
10. Singh AD, Kaiser PK, Sears JE, Gupta M, Rundle PA, Rennie IG: Photodynamic therapy of circumscribed choroidal haemangioma. Br J Ophthalmol 2004;88:1414-1418.
11. Porrini G, Giovannini A, Amato G, Ioni A, Pantanetti M: Photodynamic therapy of circumscribed choroidal hemangioma. Ophthalmology 2003;110:674-680.
12. Verbraak FD, Schlingemann RO, Keunen JE, de Smet MD: Longstanding symptomatic choroidal hemangioma managed with limited PDT as initial or salvage therapy. Graefes Arch Clin Exp Ophthalmol 2003;241:891-898.
13. Huiskamp EA, Muskens RP, Ballast A, Hooymans JM: Diffuse choroidal haemangioma in Sturge-Weber syndrome treated with photodynamic therapy under general anaesthesia. Graefes Arch Clin Exp Ophthalmol 2005;243:727-730.
14. Bains HS, Cirino AC, Ticho BH, Jampol LM: Photodynamic therapy using verteporfin for a diffuse choroidal hemangioma in Sturge-Weber syndrome. Retina 2004;24:152-155.
15. Shields JA: Photodynamic therapy for choroidal hemangioma. Graefes Arch Clin Exp Ophthalmol 2006;244:1071-1072.
16. Jurklies B, Bornfeld N: The role of photodynamic therapy in the treatment of symptomatic choroidal hemangioma. Graefes Arch Clin Exp Ophthalmol 2005;243:393-396.
17. Vicuna-Kojchen J, Banin E, Averbukh E, Barzel I, Shulman M, Hemo I, Pe'er J, Chowers I: Application of the standard photodynamic treatment protocol for symptomatic circumscribed choroidal hemangioma. Ophthalmologica 2006;220:351-355.
18. Webster AR, Maher ER, Moore AT: Clinical characteristics of ocular angiomatosis in von Hippel-Lindau disease and correlation with germline mutation. Arch Ophthalmol 1999;117:371-378.
19. Atebara NH: Retinal capillary hemangioma treated with verteporfin photodynamic therapy. Am J Ophthalmol 2002;134:788-790.
20. Javellana JA, Drouilhet JH, Kokame GT, Chee PH, Wong BM: Retinal capillary angioma in familial exudative vitreoretinopathy treated with photodynamic therapy. Am J Ophthalmol 2004;137:780-782.
21. Costa RA, Meirelles RL, Cardillo JA, Abrantes ML, Farah ME: Retinal capillary hemangioma treatment by indocyanine green-mediated photothrombosis. Am J Ophthalmol 2003;135:395-398.
22. Schmidt-Erfurth UM, Kusserow C, Barbazetto IA, Laqua H: Benefits and complications of photodynamic therapy of papillary capillary hemangiomas. Ophthalmology 2002;109:1256-1266.
23. Obana A, Goto Y, Ikoma M: A case of von Hippel-Lindau disease with papillary capillary hemangioma treated by photodynamic therapy. Nippon Ganka Gakkai Zasshi 2004;108:226-232.
24. Aaberg TM Jr, Aaberg TM Sr, Martin DF, Gilman JP, Myles R: Three cases of large retinal capillary hemangiomas treated with verteporfin and photodynamic therapy. Arch Ophthalmol 2005;123:328-332.
25. Szabo A, Gehl Z, Seres A: Photodynamic (verteporfin) therapy for retinal capillary haemangioma, with monitoring of feeder and draining blood vessel diameters. Acta Ophthalmol Scand 2005;83:512-513
26. Golshevsky JR, O'Day J: Photodynamic therapy in the management of juxtapapillary capillary haemangiomas. Graefes Arch Clin Exp Ophthalmol 2005;33:509-512.
27. Gass JD, Braunstein R: Sessile and exophytic capillary angiomas of the juxtapapillary retina and optic nerve head. Arch Ophthalmol 1980;98:1790-1797.
28. Barbazetto IA, Lee TC, Rollins IS, Chang S, Abramson DH: Treatment of choroidal melanoma using photodynamic therapy. Am J Ophthalmol 2003;135:898-899.
29. Wachtlin J, Bechrakis NE, Foerster MH: Photodynamic therapy with verteporfin for uveal melanoma: a clinical histopathological pilot study. Ophthalmologe 2005;102:241-246.
30. Rodriguez-Coleman H, Spaide RF, Yannuzzi LA: Treatment of angiomatous lesions of the retina with photodynamic therapy. Retina 2002;22:228-232.
31. Barbazetto IA, Smith RT: Vasoproliferative tumor of the retina treated with PDT. Retina 2003;23:565-567.
32. Barbazetto IA, Lee TC, Abramson DH: Treatment of conjunctival squamous cell carcinoma with photodynamic therapy. Am J Ophthalmol 2004;138:183-189.
33. Rossi R, Puccioni M, Mavilia L, Campolmi P, Mori M, Cappuccini A, Reali EF, Cappugi P: Squamous cell carcinoma of the eyelid treated with photodynamic therapy. J Chemother 2004;16:306-309.
34. Piccolino FC, Borgia L: Central serous chorioretinopathy and indocyanine green angiography. Retina 1994;14:231-242.
35. Guyer DR, Yannuzzi LA, Slakter JS, Sorenson JA, Ho A, Orlock D: Digital indocyanine green videoangiography of central serous chorioretinopathy. Arch Ophthalmol 1994;112:1057-1062.
36. Spaide RF, Hall L, Haas A, Campeas L, Yannuzzi LA, Fisher YL, Guyer DR, Slakter JS, Sorenson JA, Orlock DA: Indocyanine green videoangiography of older patients with central serous chorioretinopathy. Retina 1996;16:203-213.
37. Yannuzzi LA, Slakter JS, Gross NE, Spaide RF, Costa DL, Huang SJ, Klancnik JM Jr, Aizman A: Indocyanine green angiography-guided photodynamic therapy for treatment of chronic central serous chorioretinopathy: a pilot study. Retina 2003;23:288-298.
38. Cardillo Piccolino F, Eandi CM, Ventre L, Rigault de la Longrais RC, Grignolo FM: Photodynamic therapy for chronic central serous chorioretinopathy. Retina 2003;23:752-763.
39. Chan WM, Lam DS, Lai TY, Tam BS, Liu DT, Chan CK: Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at the primary disease level. Br J Ophthalmol 2003;87:1453-1458.
40. Canakis C, Livir-Rallatos C, Panayiotis Z, Livir-Rallatos G, Persidis E, Conway MD, Peyman GA: Ocular photodynamic therapy for serous macular detachment in the diffuse retinal pigment epitheliopathy variant of idiopathic central serous chorioretinopathy. Am J Ophthalmol 2003;136:750-752.
41. Taban M, Boyer DS, Thomas EL, Taban M: Chronic central serous chorioretinopathy: photodynamic therapy. Am J Ophthalmol 2004;137:1073-1080.
42. Ober MD, Yannuzzi LA, Do DV, Spaide RF, Bressler NM, Jampol LM, Angelilli A, Eandi CM, Lyon AT: Photodynamic therapy for focal retinal pigment epithelial leaks secondary to central serous chorioretinopathy. Ophthalmology 2005;112:2088-2094.
43. De Lahitte GD, Cohen SY, Gaudric A: Lack of apparent short-term benefit of photodynamic therapy in bilateral, acquired, parafoveal telangiectasia without subretinal neovascularization. Am J Ophthalmol 2004;138:892-894.
44. Schmidt-Erfurth U, Hasan T, Schomacker K, Flotte T, Birngruber R: In vivo uptake of liposomal benzoporphyrin derivative and photothrombosis in experimental corneal neovascularization. Lasers Surg Med 1995;17:178-188.
45. Holzer MP, Solomon KD, Vroman DT, Sandoval HP, Margaron P, Kasper TJ, Crosson CE: Photodynamic therapy with verteporfin in a rabbit model of corneal neovascularization. Invest Ophthalmol Vis Sci 2003;44:2954-2958.
46. Fossarello M, Peiretti E, Zucca I, Serra A: Photodynamic therapy of corneal neovascularization with verteporfin. Cornea 2003;22:485-488.
47. Parodi MB, Iacono P: Photodynamic therapy with verteporfin for anterior segment neovascularizations in neovascular glaucoma. Am J Ophthalmol 2004;138:157-158.
48. Muller VA, Ruokonen P, Schellenbeck M, Hartmann C, Tetz M: Treatment of rubeosis iridis with photodynamic therapy with verteporfin - a new therapeutic and prophylactic option for patients with the risk of neovascular glaucoma? Ophthalmic Res 2003;35:60-64.
49. Mimouni KF, Bressler SB, Bressler NM: Photodynamic therapy with verteporfin for subfoveal choroidal neovascularization in children. Am J Ophthalmol 2003;135:900-902.
50. Harissi-Dagher M, Sebag M, Gauthier D, Marcil G, Labelle P, Arbour JD: Photodynamic therapy in young patients with choroidal neovascularization following traumatic choroidal rupture. Am J Ophthalmol 2005;139:726-728.
51. Giansanti F, Virgili G, Varano M, Tedeschi M, Rapizzi E, Giacomelli G, Menchini U: Photodynamic therapy for choroidal neovascularization in pediatric patients. Retina 2005;25:590-596.
52. Potter MJ, Szabo SM, Ho T: Combined photodynamic therapy and intravitreal triamcinolone for the treatment of myopic choroidal neovascularization in a 13-year-old girl. Graefes Arch Clin Exp Ophthalmol 2006;244:639-641.
53. Postelmans L, Pasteels B, Coquelet P, El Ouardighi H, Verougstraete C, Schmidt-Erfurth U: Severe pigment epithelial alterations in the treatment area following photo-dynamic therapy for classic choroidal neovascularization in young females. Am J Ophthalmol 2004;138:803-808.
54. Wachtlin J, Behme T, Heimann H, Kellner U, Foerster MH: Concentric retinal pigment epithelium atrophy after a single photodynamic therapy. Graefes Arch Clin Exp Ophthalmol 2003;241:518-521.
55. Stur M: The potential and the limits of photodynamic therapy - a review. Klin Monatsbl Augenheilkd 2003;220:654-668.
56. Hopley C, Salkeld G, Mitchell P: Cost utility of photodynamic therapy for predominantly classic neovascular age related macular degeneration. Br J Ophthalmol 2004;88:982-987.
57. Jonas JB, Spandau UH, Kamppeter BA, Harder B: Follow-up after intravitreal triamcinolone acetonide for exudative age-related macular degeneration. Eye 2007;21:387-394.
58. Chan WM, Lai TY, Wong AL, Tong JP, Liu DT, Lam DS: Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of subfoveal choroidal neovascularisation in age related macular degeneration: a comparative study. Br J Ophthalmol 2006;90:337-341.
59. Nicolo M, Ghiglione D, Lai S, Nasciuti F, Cicinelli S, Calabria G: Occult with no classic choroidal neovascularization secondary to age-related macular degeneration treated by intravitreal triamcinolone and photodynamic therapy with verteporfin. Retina 2006;26:58-64.
60. Spaide RF, Sorenson J, Maranan L: Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization. Ophthalmology 2005;112:301-304.
61. Augustin AJ, Schmidt-Erfurth U: Verteporfin therapy combined with intravitreal triamcinolone in all types of choroidal neovascularization due to age-related macular degeneration. Ophthalmology 2006;113:14-22.
62. Slakter JS, Bochow TW, D'Amico DJ, Marks B, Jerdan J, Sullivan EK, Robertson SM, Slakter JS, Sullins G, Zilliox P; Anecortave Acetate Clinical Study Group: Anecortave acetate (15 milligrams) versus photodynamic therapy for treatment of subfoveal neovascularization in age-related macular degeneration. Ophthalmology 2006;113:3-13.
63. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR; VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group: Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-2816.
64. Heier JS, Boyer DS, Ciulla TA, Ferrone PJ, Jumper JM, Gentile RC, Kotlovker D, Chung CY, Kim RY: Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study. Arch Ophthalmol 2006;124:1532-1542.
65. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ: Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006;113:363-372.
66. Ladewig MS, Ziemssen F, Jaissle G, Helb HM, Scholl HP, Eter N, Bartz-Schmidt KU, Holz FG: Intravitreal bevacizumab for neovascular age-related macular degeneration. Ophthalmologe 2006;103:463-470.
67. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S; ANCHOR Study Group: Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-1444.
68. Mennel S, Hausmann N, Meyer CH, Horle S, Peter S: Transient visual decrease after photodynamic therapy. Ophthalmologe 2005;102:58-63.
69. Mennel S, Meyer CH: Transient visual disturbance after photodynamic therapy. Am J Ophthalmol 2005;139:748-749.
70. Costa RA, Farah ME, Cardillo JA, Calucci D, Williams GA: Immediate indocyanine green angiography and optical coherence tomography evaluation after photodynamic therapy for subfoveal choroidal neovascularization. Retina 2003;23:159-165.
71. Mennel S, Peter S, Meyer CH, Thumann G: Effect of photodynamic therapy on the function of the outer blood-retinal barrier in an in vitro model. Graefes Arch Clin Exp Ophthalmol 2006;244:1015-1021.
72. Schmidt-Erfurth U, Schlotzer-Schrehard U, Cursiefen C, Michels S, Beckendorf A, Naumann GO: Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor. Invest Ophthalmol Vis Sci 2003;44:4473-4480.
73. Framme C, Flucke B, Birngruber R: Comparison of reduced and standard light application in photodynamic therapy of the eye in two rabbit models. Graefes Arch Clin Exp Ophthalmol 2006;244:773-781.
74. Mennel S, Meyer CH, Zaki NV, Schmidt JC: Photodynamic therapy - why and when to add antiproliferative adjuvants. Spektrum Augenheilkd 2006;20:58.
75. Michels S, Wachtlin J, Gamulescu MA, Heimann H, Prunte C, Inhoffen W, Krebs I, Schmidt-Erfurth U: Comparison of early retreatment with the standard regimen in verteporfin therapy of neovascular age-related macular degeneration. Ophthalmology 2005;112:2070-2075.
76. Rodriguez-Coleman H, Yuan P, Kim H, Gravlin L, Srivastava S, Csaky KG, Robinson MR: Intravitreal injection of triamcinolone for diffuse macular edema. Arch Ophthalmol 2004;122:1085-1086.